Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 12/20 | 0.69 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | TNKS | O95271 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.41 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.41 |
| ▸ | DAO | P14920 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CCR4 | P51679 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2966714 | 0.83 | PGR (0.66) | PGRPOLBDAOMAOBCCR4 | |
| SCHEMBL20079372 | 0.83 | PGR (0.49) | PGRTNKSCYP3A4TNKS2PARP2 | |
| SCHEMBL16883635 | 0.81 | LMNA (0.49) | PGRTNKSCYP3A4TNKS2PARP2 | |
| SCHEMBL31473423 | 0.81 | LMNA (0.49) | PGRTNKSCYP3A4TNKS2PARP2 | |
| SCHEMBL2973703 | 0.76 | PGR (0.57) | PGRPOLBDAOMAOBCCR4 | |
| SCHEMBL16858454 | 0.75 | LMNA (0.49) | PGRTNKSCYP3A4TNKS2PARP2 | |
| SCHEMBL20079384 | 0.74 | PGR (0.58) | PGRPOLBDAOMAOBAR | |
| SCHEMBL20079378 | 0.74 | POLB (0.55) | PGRPOLBTNKSMAOB | |
| SCHEMBL20079379 | 0.74 | PGR (0.65) | PGRPOLBMAOB | |
| SCHEMBL18358719 | 0.72 | PSMB8 (0.44) | PGRTNKSCYP3A4TNKS2PARP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200179357-A1 | TRPA1 ANTAGONISTS FOR TREATMENT OF DRY EYE, OCULAR PAIN AND INFLAMMATION | ALGOMEDIX INC (US) | 2020-06-11 | — | — | US | disclosed |
| US-10428049-B2 | TRPA1 modulators | ALGOMEDIX, INC. (US) | 2019-10-01 | — | — | US | disclosed |
| US-20190016701-A1 | TRPA1 MODULATORS | ALGOMEDIX, INC. (US) | 2019-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428049-B2 | TRPA1 modulators | TRPA1, TRPV1, TRPV2 | PGR 3776/4885POLB 4513/4885TNKS 1618/4885 |
| US-20190016701-A1 | TRPA1 MODULATORS | TRPA1, TRPV1, TRPV2 | PGR 3776/4885POLB 4513/4885TNKS 1618/4885 |
| US-20200179357-A1 | TRPA1 ANTAGONISTS FOR TREATMENT OF DRY EYE, OCULAR PAIN AND INFLAMMATION | TRPA1, TRPV1, TRPV2 | PGR 4156/4885POLB 4439/4885TNKS 2848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.